Sivia Capital Partners LLC Has $401,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Sivia Capital Partners LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,580 shares of the biopharmaceutical company’s stock after purchasing an additional 262 shares during the quarter. Sivia Capital Partners LLC’s holdings in Gilead Sciences were worth $401,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Bridgewater Associates LP increased its position in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company’s stock worth $42,577,000 after purchasing an additional 253,994 shares in the last quarter. Nissay Asset Management Corp Japan ADV increased its position in Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company’s stock worth $26,750,000 after purchasing an additional 14,009 shares in the last quarter. NatWest Group plc acquired a new position in Gilead Sciences during the 4th quarter worth approximately $6,808,000. Empowered Funds LLC increased its position in Gilead Sciences by 55.8% during the 4th quarter. Empowered Funds LLC now owns 219,579 shares of the biopharmaceutical company’s stock worth $20,283,000 after purchasing an additional 78,657 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board increased its position in Gilead Sciences by 54.6% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company’s stock valued at $3,422,000 after acquiring an additional 13,086 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares of the company’s stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 17,929 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This trade represents a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,929 shares of company stock valued at $6,748,980. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several recent research reports. Bank of America upped their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Stock Up 1.8%

Shares of NASDAQ GILD opened at $112.46 on Friday. The firm has a market cap of $139.89 billion, a PE ratio of 303.95, a P/E/G ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96. The company’s fifty day simple moving average is $105.39 and its 200 day simple moving average is $101.56. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.32) earnings per share. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.81%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio is presently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.